# Can SS-31 (Elamipretide) improve cardiovascular function in heart failure?

Canonical source: https://retacompare.com/research/can-ss-31-elamipretide-improve-cardiovascular-function-in-heart-failure

Peptide Longevity Q&A · 2026-01-21


    Research indicates that SS-31 (Elamipretide) enhances mitochondrial respiration in a rodent model of heart failure with preserved ejection fraction (HFpEF). However, this improvement did not translate into functional or structural benefits, suggesting limited therapeutic efficacy in established HFpEF.


What the research shows

The study focused on the effects of SS-31 (Elamipretide) on cardiac mitochondrial function and overall cardiovascular performance in a rodent model of heart failure with preserved ejection fraction (HFpEF). Female obese ZSF1 rats received either a vehicle or Elamipretide treatment for a duration of 12 weeks, with age-matched lean rats serving as controls. The researchers assessed cardiac function and hemodynamics through echocardiography and pressure-volume analysis. Additionally, mitochondrial respiration was measured in permeabilized fibers, while the ultrastructure of mitochondria was evaluated using transmission electron microscopy. The study also included molecular and histological analyses, focusing on cardiolipin lipidomics and the profiling of various markers related to hypertrophy, fibrosis, and inflammation.


Why it matters for longevity

The findings from this research are significant for understanding the role of mitochondrial function in cardiovascular health, particularly in aging populations. Mitochondrial dysfunction is a known contributor to heart failure and age-related decline in cardiac performance. While SS-31 showed a modest improvement in mitochondrial respiration, the lack of corresponding functional benefits raises questions about its effectiveness as a therapeutic strategy for heart failure, especially in older adults where HFpEF is prevalent. This highlights the complexity of treating age-related cardiovascular conditions and the need for further research to explore potential interventions that could enhance both mitochondrial function and overall heart health.


Key findings at a glance

SS-31 (Elamipretide) improved mitochondrial respiration in a rodent model.

No significant changes were observed in cardiac function or structure after treatment.

Diastolic dysfunction persisted despite enhanced mitochondrial function.

Cardiac remodeling markers such as hypertrophy and fibrosis remained unchanged.

Vascular stiffness slightly increased, indicating potential concerns for vascular health.


How SS-31 (Elamipretide) works (background)

SS-31 (Elamipretide) is a peptide designed to target mitochondria, aiming to improve mitochondrial bioenergetics. By enhancing mitochondrial function, it is theorized that the peptide could mitigate some of the detrimental effects of mitochondrial dysfunction, which is associated with various age-related diseases, including heart failure. In preclinical models, SS-31 has shown promise in enhancing mitochondrial respiration, which is crucial for maintaining energy production in cardiac cells. However, the study suggests that merely improving mitochondrial respiration does not necessarily lead to improved cardiac function in the context of established heart failure.


Safety, caveats, and what we don't yet know

While the research provides valuable insights, it is important to note that it was conducted in a preclinical model. The findings may not directly translate to human populations, particularly those with different underlying health conditions or comorbidities. Additionally, the study did not explore the long-term effects of SS-31 treatment or its impact on other aspects of cardiovascular health. Future research is needed to determine the full therapeutic potential of SS-31, including its efficacy in various stages of heart failure and its safety profile in human subjects.


Bottom line

In summary, SS-31 (Elamipretide) showed some improvement in mitochondrial respiration in a rodent model of HFpEF, but this did not result in functional or structural benefits, indicating limited therapeutic efficacy for cardiovascular aging.


Related questions

Does SS-31 (Elamipretide) have potential for improving vascular health?

Research indicates that while SS-31 may enhance mitochondrial function, its effects on vascular health are less clear, as vascular stiffness increased in the study.

What are the implications of mitochondrial dysfunction in aging?

Mitochondrial dysfunction is linked to various age-related diseases, including heart failure. Improving mitochondrial function may be key to enhancing overall healthspan.

How does SS-31 (Elamipretide) compare to other longevity peptides?

While SS-31 focuses on mitochondrial function, other peptides may target different pathways in aging. Comparative studies are needed to evaluate their relative effectiveness.


Source: PubMed · Int J Mol Sci · published 2026-01-21.

## Sources

- PubMed · Int J Mol Sci: https://pubmed.ncbi.nlm.nih.gov/41596703/